[Prediction of changes in bone density during alendronate treatment in postmenopausal women].

Alendronate is an aminobisphosphonate, a selective inhibitor of osteoclast-mediated bone resorption. Due to its influence a decline of markers of bone turnover occurs. The latter react much sooner than it is possible to detect significant changes of bone density.

Coexistence of ochronosis and rheumatoid arthritis: a cause of delay in diagnosis and treatment.

Two rheumatic diseases can often coexist despite the interesting fact that gout and rheumatoid arthritis (RA) are infrequently associated. We describe a patient with familial history of alkaptonuria and rheumatoid arthritis who developed both diseases. The exact time of onset of the RA was difficult to ascertain.